🥳 How are you planning to celebrate #WorldLiverDay? And what do you do to strengthen your own liver? #SolidHabitsStrongLiver

👉 Eat healthy - daily 🥦
👉 Move your body - daily 🥎🎾🏃‍➡️
👉 Reduce alcohol - always🍷 ➡️ 🥛 (there is no "safe" amount of alcohol)
👉 Get your liver checked regularly by a doctor 🩺

📣 IMAC invites you to an upcoming webinar examining how evidence in rare disease trials can be interpreted more rigorously.

🎓 𝗙𝗿𝗼𝗺 𝗙𝘂𝘁𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴: 𝗪𝗵𝗮𝘁 𝗮 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗟𝗲𝗻𝘀 𝗥𝗲𝘃𝗲𝗮𝗹𝘀 𝗶𝗻 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗶𝗮𝗹𝘀

📅 April 9
⏰ 4:00 pm CET

👉 Register here: events.teams.microsoft.com/event/9ed2de...

Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts Acute-on-chronic liver failure (ACLF) is characterised by multiorgan failure and high short-term mortality in hospitalised cirrhosis patients with acu…

📣 New publication introducing the A-TANGO Organ Failure (OF) score for improved detection of acute-on-chronic liver failure #ACLF in patients with acute #decompensation of #cirrhosis

👍3,896 patients
👍validated in India & China
👍improves diagnostic accuracy

www.sciencedirect.com/science/arti...

This gives us the opportunity to
👉 order a new batch of drugs (manufacturing duration: 3 months)
👉 open more sites in the UK
👉 obtain regulatory approval in Europe / India
👉 include patients in the G-TAK Trial (starting in April)
👉 develop a credible scenario for a further project extension

🚀 Motivation boost to kick off the new year 🙂: The European Commission agreed to provide a 6-month-long extension to A-TANGO! Let's use this momentum and move forward swiftly now, so that A-TANGO can bring the much-needed G-TAK therapy for severe #AlcoholicHepatitis #cirrhosis #ACLF to the market.

🥂 We have good news for the holidays: The technical hold-up in the EU portal has finally been resolved & we submitted the 3rd #PeriodicReport ☺️

Wishing everyone relaxing holidays❄️

Together, we are moving from bench to bedside to bring innovative therapies to #ACLF patients

@rajivjalan.bsky.social

New calls & Project highlights from concentris Calls opening soon *** EU Clusters in cancer prevention & environmental health, *** New QSPainRelief Database *** Important Policy Recommendations for people with Down syndrome from GO-DS21 *** Pediat...

As the year draws to a close, we are wrapping up 2025 with gratitude, momentum, and a spirit of community at concentris. ✨

💡Curious about what’s next in 2026, and how these developments could support your work?
Read our latest #newsletter:
🔗 mailchi.mp/concentris/n...

On Wednesday, 26 Nov, at 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance”

The episode will be broadcast live on EASL.eu and can be accessed here:

📹 easl.eu/easl-studio-...

Don't miss it ☺️

👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF!

#BenchToBedside #cirrhosis
@rajivjalan.bsky.social

For #WorldHepatitisDay we stand together 🩺

At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️

Every person deserves timely, effective, and #stigma‑free support 💪

@europeliver.bsky.social
@who.int

What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊

#AlcoholicHepatitis

@europeliver.bsky.social
@easlnews.bsky.social

Join this exciting event!

Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities!

🚀 Register now: inevent.uk/en/Crowdheli...

The #LiverHealth Helix Event acts as a platform for sharing experiences regarding #DrugDevelopment challenges in #ClinialTrials + fostering collaboration between attendees.

Key Objectives:
🔵 Communicate A-TANGO’s results
🔵 Connect industry & scientific community
🔵 Showcase the Liver Health Helix

📣 Secure your spot now 📣:
inevent.uk/en/Crowdheli...

Check out our upcoming (online) A-TANGO #LiverHealth Helix Event!

🟣 Industrial Perspective on #DrugDevelopment Challenges for #ClinicalTrials
🗓️ 04 June 2025
🕙 Begin: 10 am BST

#ClinicalResearch
@rajivjalan.bsky.social
@easlnews.bsky.social

We really appreciate the fantastic talk and continued collaboration with ELPA @europeliver.bsky.social! 🎉🙏

At #EASL2025, ELPA President Marko Korenjak presented 3 EU projects: A-TANGO, LIVER AIM & THRIVE.

At the Layperson Events, science met real stories — patients at the center of innovation, action & hope.

@liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social

Using this for the final #ConsensusConference of A-TANGO - to evaluate #GTAK trial outcomes & agree on the best treatment for #LiverPatients with #ACLF.

👉 The name comes from the ancient Greek „Oracle of Delphi“ 🔮🇬🇷

👉 The Delphi Method evolved during the Cold War for strategic military decisions 🕊️☮️

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.

🗓️ What a fun #workshop at #EASLCongress 2025

🧠 SAT-210 – #EASL2025

New tool alert!

The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team!

#LiverHealth #HE #ClinicalResearch

🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis

👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress

👉 Is #alcohol-related #hepatitis in ACLF its own beast?
👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis?

Chair @rajivjalan.bsky.social

👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏

🥳 TOP-217-YI 🥳

Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications

Today’s #readoftheweek📚 highlights the presence of inflammation and bacterial products in the systemic circulation in patients with compensated #cirrhosis and clinically significant portal hypertension.

Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...

#LiverSky

🥳 SATURDAY 🥳

If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité

#AlcoholicHepatitis #cirrhosis #ACLF #inflammation

@rajivjalan.bsky.social
@medblab.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social

Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress:

FRI-197
The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium

Crucial for understanding the disease progression!
@rajivjalan.bsky.social

🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏

👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate

👍 In A-TANGO, we use #TAK242 + G-CSF

🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️!
#ACLF #cirrhosis #LiverFailure

💲💰 Wake up your inner #entrepreneur, found your own start-up #company #business, and learn from expert @rajivjalan.bsky.social about how to manage financial conflicts of interest #COI

Today at #EASLCongress as part of a #YoungInvestigator Seminar!

📍 Erlinger Room
📅 Thurs, May 8
⏲️ 15:35 - 15:45 h

📣 Today: #POSTER TOP-203, congrats 🥳

A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL

👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF

👉 Topic: Cirrhosis & Complications

#LiverFailure #ACLF
@rajivjalan.bsky.social

📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL

👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction

#Cirrhosis & Complications

#ACLF #LiverFailure
@rajivjalan.bsky.social